February 16th, 2007


The VentureOne hybrid vehicle.

Introducing the VentureOne, a revolutionary 3-wheel, tilting, plug-in Hybrid vehicle. This unique 2-passenger flex-fuel Hybrid vehicle will achieve 100 miles per gallon, accelerate from 0-60 in 6 seconds with a top speed of over 100 mph, yet at a retail price of under $20,000.

And if that weren’t enough, imagine combining the performance feel of a sports car with the agility of a motorcycle. This is an exhilarating driving experience that can only be compared to flying a jet fighter two feet off the ground.


It's a trike motorcycle with a roll cage and an electric motor. And I have to admit, I like it. It looks cool, and I see no reason a car that small can't get 100 MPG. Now, I do believe that parallel hybrids are superior on general principle. And I would like to see it use a flywheel regenerator instead of taking the efficiency hit that electric regen entails. But all in all, looks damn good. We'll see if they can deliver on the promises their rather breathless prose makes.

Geordi, we hardly knew ye. Silicon retinas already undergoing human trials.


The user wears a pair of glasses that contain a miniature camera and that wirelessly transmits video to a cellphone-sized computer in the wearer's pocket. This computer processes the image information and wirelessly transmits it to a tiny electronic receiver implanted in the wearer's head.

The received in the implanted chip, the digital information is transformed into electrical impulses sent into the ganglion cells. From there, the brain takes over as the information travels down the optic nerve to the visual cortex at the back of the brain. The whole process occurs extremely rapidly, so that patients see in real-time. This is important any noticeable lag could stimulate the "vestibular-ocular reflex", making people feel dizzy and sick.

Humayun's team is about to embark on a new trial of an improved device, which they will fit into 50 to 75 people aged over 50, who are also blind as a result of retinitis pigmentosa. The trial will involve monitoring them for two years and will take place in five centres across the US.